What is the current Acceleron Pharma market capitalization?
The current market capitalization of Acceleron Pharma is 10.15 B USD.
Acceleron Pharma Market capitalization 2024
Acceleron Pharma Market capitalization
10.15 B USD
Acceleron Pharma Dividend yield
Ticker
XLRN
ISIN
US00434H1086
WKN
A1W5LE
In 2024, Acceleron Pharma's market cap stood at 10.15 B USD, a 46.37% increase from the 6.94 B USD market cap in the previous year.
The Acceleron Pharma Market capitalization history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) | NET INCOME (undefined USD) |
|---|---|---|---|
| 2025e | 642.76 | 2,37 | -203.71 |
| 2024e | 436.36 | 3,49 | -159.77 |
| 2023e | 302.16 | 5,05 | -127.82 |
| 2022e | 215.16 | 7,09 | -204.43 |
| 2021e | 139.56 | 10,93 | -247.87 |
| 2020 | 92.52 | 16,48 | -166.03 |
| 2019 | 73.99 | 20,61 | -124.86 |
| 2018 | 13.99 | 109,01 | -118.87 |
| 2017 | 13.48 | 113,13 | -108.45 |
| 2016 | 27.77 | 54,92 | -57.01 |
| 2015 | 18.1 | 84,25 | -63.89 |
| 2014 | 14.63 | 104,24 | -51.26 |
| 2013 | 57.23 | 26,65 | -21.9 |
| 2012 | 15.25 | 100,00 | -32.58 |
| 2011 | 80.91 | 98,15 | 36.27 |
Acceleron Pharma Aktienanalyse
What does Acceleron Pharma do?
Acceleron Pharma Inc. is a biopharmaceutical company based in Cambridge, Massachusetts. It was founded in 2003 by a group of scientists specializing in drug development in the fields of oncology and hematology. The company's business model is based on the discovery and development of innovative therapeutic solutions, particularly in the areas of oncology and rare diseases. They use a wide range of technologies to identify potential target molecules and test their effectiveness. Acceleron Pharma operates in three different business areas: oncology, hemoglobinopathies, and musculoskeletal diseases. In oncology, the company focuses on developing drugs to treat cancers such as multiple myeloma or pancreatic cancer. The hemoglobinopathies division of Acceleron Pharma develops therapies for patients with rare blood disorders such as beta-thalassemia and sickle cell disease. In the field of musculoskeletal diseases, the company is working on developing therapies for muscle, connective tissue, and joint disorders. One of Acceleron Pharma's key products is the drug Reblozyl, which was developed in collaboration with Bristol Myers Squibb. Reblozyl is the first FDA-approved medication for the treatment of anemia in patients with beta-thalassemia. The company has also entered into a partnership agreement with Celgene to develop medications for the treatment of inflammatory bowel diseases. Acceleron Pharma has also successfully partnered with other major pharmaceutical companies such as Pfizer and Sanofi in the past. Through these partnerships, the company has provided its technology platform for the discovery and development of drugs for various indications such as cancer and muscle diseases. Acceleron Pharma is a fast-growing company dedicated to researching and developing innovative therapies for rare diseases. With a wide range of technologies and a strong pipeline of clinical candidates, the company is well-equipped to treat patients affected by these rare diseases. Acceleron Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Acceleron Pharma's Market Capitalization
Acceleron Pharma's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Acceleron Pharma's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Acceleron Pharma's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Acceleron Pharma’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Acceleron Pharma Stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Acceleron Pharma.
How has the market capitalization of Acceleron Pharma developed in recent years?
The market capitalization of Acceleron Pharma has increased/decreased by 46.37% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Acceleron Pharma?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Acceleron Pharma?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Acceleron Pharma have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Acceleron Pharma pay?
Over the past 12 months, Acceleron Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acceleron Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of Acceleron Pharma?
The current dividend yield of Acceleron Pharma is .
When does Acceleron Pharma pay dividends?
Acceleron Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Acceleron Pharma?
Acceleron Pharma paid dividends every year for the past 0 years.
What is the dividend of Acceleron Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Acceleron Pharma located?
Acceleron Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Acceleron Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Acceleron Pharma from 5/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/20/2024.
When did Acceleron Pharma pay the last dividend?
The last dividend was paid out on 5/20/2024.
What was the dividend of Acceleron Pharma in the year 2023?
In the year 2023, Acceleron Pharma distributed 0 USD as dividends.
In which currency does Acceleron Pharma pay out the dividend?
The dividends of Acceleron Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Acceleron Pharma stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Acceleron Pharma
Our stock analysis for Acceleron Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acceleron Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Acceleron Pharma Revenue
- Acceleron Pharma Net Income
- Acceleron Pharma P/E
- Acceleron Pharma P/S
- Acceleron Pharma EBIT
- Acceleron Pharma Dividend
- Acceleron Pharma Stocks
- Acceleron Pharma Market capitalization
- Acceleron Pharma Debt
- Acceleron Pharma Liabilities
- Acceleron Pharma Equity
- Acceleron Pharma AAQS
- Acceleron Pharma Employees
- Acceleron Pharma ROE
- Acceleron Pharma ROA
- Acceleron Pharma ROCE
